Nevertheless, the prospective enrichment of LSCs in B-ALL using the CD34 and CD38 surface markers, associated or not with CD19, led to highly variable results [37,42,43,44]. The gene discussed is CD34; the disease is precursor B-cell acute lymphoblastic leukemia.